April Webinar RegistrationApril Webinar Registration


Dow Jones Futures Rise On Stimulus Deal Hopes With Jobs Report In Focus; DocuSign Eyes Buy Points

Dow Jones futures rose slightly Friday morning, along with S&P 500 futures and Nasdaq futures, ahead of the November jobs report, with coronavirus vaccine news and stimulus deal talks in focus.

X

The stock market rally turned mixed Wednesday on an afternoon report that detailed the supply chain issues that spurred Pfizer (PFE) and BioNTech (BNTX) weeks ago to halve the the number of coronavirus vaccine doses by year-end. Coming right ahead of the close, investors took the Pfizer vaccine production cut as brand-new.

Pfizer stock and BioNTech fell on the initial headlines, while rival Covid-19 vaccine maker Moderna (MRNA) soared.

After the close, DocuSign (DOCU) headlined after-hours earnings reports. DocuSign stock jumped early Friday, signaling an early entry and nearing a buy point. That followed earnings breakouts Thursday by CrowdStrike (CRWD), Zscaler (ZS) and Elastic (ESTC).

Stimulus Deal 'Hopeful Signs'

House Speaker Nancy Pelosi and Senate Majority Leader Mitch McConnell spoke Thursday to reaffirm their commitment to a new coronavirus stimulus deal, as lawmakers signal more willingness to compromise and reach an agreement soon. McConnell said earlier in the day that he sees "hopeful signs" for a stimulus deal. Pelosi and Senate Minority Leader Chuck Schumer said Wednesday that a new $908 billion bipartisan proposal could form the basis for stimulus deal talks.

A Dec. 11 deadline for government funding looms.

CrowdStrike stock and Zscaler joined IBD Leaderboard on Thursday.

Dow Jones Futures Today

Dow Jones futures were up 0.3% vs. fair value. S&P 500 futures climbed 0.3%. Nasdaq 100 futures rose 0.2%.

Dow Jones futures will likely move at 8:30 a.m. ET, when the Labor Department releases the November jobs report. Economists expect the November jobs report to show nonfarm payrolls rose by 500,000, as the pace of recovery slows. The jobless rate is expected to dip to 6.8%.

Remember that overnight action in Dow futures and elsewhere doesn't necessarily translate into actual trading in the next regular stock market session.


Join IBD experts as they analyze actionable stocks in the stock market rally on IBD Live.


Coronavirus Vaccine Rollout Limited

Pfizer and BioNTech said weeks ago that would only be able to deliver 50 million coronavirus vaccine doses by year-end due to supply chain issues, vs. their prior goal of 100 million doses. On Thursday, a report detailed that this was due to some poor raw materials for the vaccine. They still expect to ship more than 1 billion doses of their Covid vaccine in 2021.

The U.K. just approved the Pfizer vaccine this week, with vaccinations expected to start next week. An FDA panel will review the Pfizer-BioNTech vaccine on Dec. 10 and the Moderna coronavirus vaccine a week later.

Pfizer stock fell 1.7% on Thursday, with BioNTech down 3.5%, with nearly all of the losses coming in 30 minutes on the vaccine rollout woes. Moderna stock leapt 10% to a new closing high.

In overnight trade, Pfizer and BioNTech stock fell slightly. MRNA stock edged higher.

After the close, Moderna reaffirmed its goal of 20 million doses of its coronavirus vaccine being available by year-end. It sees 100 million to 120 million available worldwide in Q1, with 500 million to 1 billion doses in 2021. It also stated that Phase 1 trial participants retained high levels of antibodies some 119 days after the first coronavirus vaccine dose — 90 days after the second dose.

Coronavirus Cases

Coronavirus cases worldwide reached 65.67 million. Covid-19 deaths topped 1.51 million.

Coronavirus cases in the U.S. have hit 14.53 million, with deaths above 282,000. Newly diagnosed U.S. Covid cases topped 218,000 so far Thursday with deaths above 2,900, both new daily records.

With local cases and hospitalizations soaring, the city of Los Angeles announced a stricter lockdown, closing all in-person activities for nonessential businesses. Walking or driving is barred, except for essential activities. The much-larger Los Angeles County had already closed down outdoor dining.

California Gov. Gavin Newsom late Thursday announced a limited stay-at-home order for many parts of the state, though his order would let nonessential retailers remain open with limited capacity.

The soaring coronavirus cases and increasing government shutdowns raise the stakes for the coronavirus vaccine rollouts and a possible stimulus deal.


Pfizer And Moderna Face Their Biggest Challenge: Vaccinating The World


Stock Market Rally Thursday

The stock market rally faltered right at the close on the Pfizer coronavirus vaccine news, after rising modestly on stimulus deal hopes.

The Dow Jones Industrial Average rose 0.3% in Thursday's stock market trading, led by Boeing (BA). The S&P 500 index lost less than 0.1%. The Nasdaq composite climbed 0.2%. Thursday's fade on higher volume means it was a stalling day for the Nasdaq.

Among the best ETFs, the Innovator IBD 50 ETF (FFTY) rose 0.2%, but closed near session lows. The iShares Expanded Tech-Software Sector ETF (IGV) climbed 0.5%. The VanEck Vectors Semiconductor ETF (SMH) lost a fraction.

Read The Big Picture every day to stay in sync with the market direction and leading stocks and sectors.


Looking For The Next Big Stock Market Winners? Start With These 3 Steps


DocuSign Earnings

DocuSign earnings doubled to 22 cents a share. Revenue rose 53% to $382.9 million, the third straight quarter of accelerating growth. Analysts expected DocuSign earnings of 13 cents on sales of $361.2 million.

The e-signature software specialist, a big winner from the work-from-home trend, also reported strong billings and guided higher for current-quarter revenue.

In premarket trading, DocuSign stock rose 6% to about 244. Briefly late Thursday, DOCU stock topped a 246.90 buy point. Investors could view 246.90 as an early entry or buy point from a very messy double-bottom base.

DOCU stock rallied 6.1% on Thursday to 231.01, rebounding from its 50-day line and breaking a trend line. That would have offered an early entry, but would have been highly risky right ahead of DocuSign earnings. If DOCU stock doesn't clear the 246.90 entry on Thursday, investors might consider starting a position based off the 10-week line.

The DocuSign earnings report follows bullish results from security software leaders CrowdStrike and Zscaler stock, as well search provider Elastic.

CrowdStrike stock spiked nearly 14% on Thursday, gapping out of a base. ZS stock leapt 26% and Elastic stock nearly 13%, also capping out of bases. CRWD stock was the IBD Stock Of The Day.

Meanwhile, Cloudera (CLDR), PagerDuty (PD) and Domo (DOMO), generally not seen as leading software names, surged Friday morning around buy points affter their quarterly results.

Please follow Ed Carson on Twitter at @IBD_ECarson for stock market updates and more.

YOU MAY ALSO LIKE:

Market Rally Outlook Pros And Cons; 5 Stocks That Are Buys Now

Why This IBD Tool Simplifies The Search For Top Stocks

Catch The Next Big Winning Stock With MarketSmith

Best Growth Stocks To Buy And Watch

IBD Digital: Unlock IBD's Premium Stock Lists, Tools And Analysis Today